Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson’s disease patients: an European multicentre survey
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1435-1463
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson’s disease patients: an European multicentre survey ; volume:127 ; number:6 ; day:5 ; month:5 ; year:2020 ; pages:875-879 ; date:6.2020
Journal of neural transmission ; 127, Heft 6 (5.5.2020), 875-879, 6.2020
- Urheber
-
Rizos, A.
Sauerbier, A.
Falup-Pecurariu, C.
Odin, P.
Antonini, A.
Martinez-Martin, P.
Kessel, B.
Henriksen, T.
Silverdale, M.
Durner, G.
Ray Chaudhuri, K.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00702-020-02168-0
- URN
-
urn:nbn:de:101:1-2020073004132642160551
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Rizos, A.
- Sauerbier, A.
- Falup-Pecurariu, C.
- Odin, P.
- Antonini, A.
- Martinez-Martin, P.
- Kessel, B.
- Henriksen, T.
- Silverdale, M.
- Durner, G.
- Ray Chaudhuri, K.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Transdermal rotigotine for the perioperative management of Parkinson’s disease
Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson’s disease
Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson’s disease
Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson’s disease
Rotigotine Transdermal Patch for Motor and Non-motor Parkinson’s Disease: A Review of 12 Years’ Clinical Experience
Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson’s disease: an open-label study
Role of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease
Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease
Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
Rotigotine transdermal system and evaluation of pain in patients with Parkinson’s disease: a post hocanalysis of the RECOVER study
Safety and tolerability of adjunct non-invasive vagus nerve stimulation in people with parkinson’s: a study protocol
Parkinson
Transdermal rotigotine for the perioperative management of Parkinson’s disease
Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson’s disease
Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson’s disease
Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson’s disease
Rotigotine Transdermal Patch for Motor and Non-motor Parkinson’s Disease: A Review of 12 Years’ Clinical Experience
Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson’s disease: an open-label study
Role of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease
Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease
Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
Rotigotine transdermal system and evaluation of pain in patients with Parkinson’s disease: a post hocanalysis of the RECOVER study
Safety and tolerability of adjunct non-invasive vagus nerve stimulation in people with parkinson’s: a study protocol
Parkinson
Transdermal rotigotine for the perioperative management of Parkinson’s disease
Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson’s disease
Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson’s disease
Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson’s disease
Rotigotine Transdermal Patch for Motor and Non-motor Parkinson’s Disease: A Review of 12 Years’ Clinical Experience
Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson’s disease: an open-label study
Role of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease
Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease
Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
Rotigotine transdermal system and evaluation of pain in patients with Parkinson’s disease: a post hocanalysis of the RECOVER study
Safety and tolerability of adjunct non-invasive vagus nerve stimulation in people with parkinson’s: a study protocol